| 0 (0%) | 10-18 04:32 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 19.05 | 1-year : | 22.16 |
| Resists | First : | 16.31 | Second : | 18.97 |
| Pivot price | 14.45  |
|||
| Supports | First : | 12 | Second : | 9.98 |
| MAs | MA(5) : | 13.1 |
MA(20) : | 14.86 |
| MA(100) : | 0 | MA(250) : | 0 | |
| MACD | MACD : | -0.9 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 20.3  |
D(3) : | 16.5 |
| RSI | RSI(14): 38.9 |
|||
| 52-week | High : | 23.39 | Low : | 8.19 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ELOX ] has closed above bottom band by 17.7%. Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 14.13 - 14.2 | 14.2 - 14.26 |
| Low: | 12.66 - 12.74 | 12.74 - 12.82 |
| Close: | 12.88 - 13.01 | 13.01 - 13.14 |
Thu, 15 Oct 2026
This Eloxx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Wed, 30 Sep 2026
ELOX stock enters a 24 patient Phase 2b kidney trial - ad-hoc-news.de
Wed, 30 Sep 2026
Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Short Interest Update - MarketBeat
Mon, 21 Sep 2026
Eloxx Pharmaceuticals, Inc. SEC Filing (Sep 21, 2026) - Stock Titan
Mon, 31 Aug 2026
Böker Gives One of Its Best Affordable EDC Knives a Cool Blue Redux - Gear Patrol
Wed, 12 Aug 2026
LifeSci Capital Maintains Eloxx Pharmaceuticals(ELOX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 931130 (%) |
| Held by Institutions | 19 (%) |
| Shares Short | 29 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 3.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 3.7 |
| PEG Ratio | 1.8 |
| Price to Book value | 1.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 53940 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|